Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: A meta-analysis of randomised controlled trials

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 7-16

  Shahin, Yousef ^a   Khan, Junaid Alam ^a   Samuel, Nehemiah ^a   Chetter, Ian ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Brachial FMD; Endothelial dysfunction; Endothelial function; Flow mediated dilatation; Renin angiotensin system

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NEBIVOLOL; NITRENDIPINE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TELMISARTAN; ZOFENOPRIL;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRACHIAL ARTERY; CALCIUM CHANNEL BLOCKERS; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASODILATION;

EID: 79955546830     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.044     Document Type: Review

References (68)

1. Drexler H. Factors involved in the maintenance of endothelial function. Am J Cardiol 1998, 82:3S-4S.
2. Inaba Y., Chen J.A., Bergmann S.R. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010, 26:631-640.
3. Kawano H., Do Y.S., Kawano Y., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130-1137.
4. Ahimastos A.A., Natoli A.K., Lawler A., Blombery P.A., Kingwell B.A. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005, 45:1194-1199.
5. Asselbergs F.W., van der Harst P., van Roon A.M., et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis 2008, 196:349-355.
6. Bots M.L., Remme W.J., Luscher T.F., et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007, 21:269-279.
7. Flammer A.J., Sudano I., Hermann F., et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008, 117:2262-2269.
8. Inanc M.T., Kalay N., Heyit T., et al. Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behcet's disease. Echocardiography 2010, 27:997-1003.
9. Koh K.K., Quon M.J., Han S.H., et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010, 140:73-81.
10. Mullen M.J., Clarkson P., Donald A.E., et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. J Am Coll Cardiol 1998, 31:1330-1335.
11. Nagamia S., Pandian A., Cheema F., et al. The role of quinapril in the presence of a weight loss regim endothelial function markers of obesity in patients with the metabolic syndrome. Prev Cardiol 2007, 10:204-209.
12. Tikiz C., Utuk O., Pirildar T., et al. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005, 32:2095-2101.
13. Williams I.L., Chowienczyk P.J., Wheatcroft S.B., et al. Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans. Diab Vasc Dis Res 2006, 3:34-38.
14. Trevelyan J., Needham E.W., Morris A., Mattu R.K. Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. Heart 2005, 91:1053-1057.
15. Ghiadoni L., Magagna A., Versari D., et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003, 41:1281-1286.
16. Koh K.K., Quon M.J., Lee Y., et al. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J 2007, 28:1440-1447.
17. Souza-Barbosa L.A., Ferreira-Melo S.E., Ubaid-Girioli S., Arantes Nogueira E., Yugar-Toledo J.C., Moreno H. Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade. J Clin Hypertens (Greenwich) 2006, 8:803-809. quiz 10-1.
18. Sozen A.B., Kayacan M.S., Tansel T., et al. Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. J Int Med Res 2009, 37:996-1002.
19. Yavuz D., Koc M., Toprak A., et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003, 4:197-203.
20. Fang L., Zheng F., Quingyin T., Ming Z., Yanyan H. Effect of ramipril on endothelial dysfunction in patients with essential hypertension. Clin Drug Invest 2002, 22:419-453.
21. Uehata A., Takase B., Nishioka T., et al. Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension. Am J Cardiol 2001, 87:1414-1416.
22. Buus N.H., Jorgensen C.G., Mulvany M.J., Sorensen K.E. Large and small artery endothelial function in patients with essential hypertension - effect of ACE inhibition and beta-blockade. Blood Press 2007, 16:106-113.
23. Pasini A.F., Garbin U., Nava M.C., et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007, 20:443-450.
24. Elbourne D.R., Altman D.G., Higgins J.P., Curtin F., Worthington H.V., Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002, 31:140-149.
25. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. Available from: ; 2008. http://www.cochrane-handbook.org/.
26. Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992, 45:769-773.
27. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
28. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomised controlled trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
29. Koh K.K., Bui M.N., Hathaway L., et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol 1999, 83:327-331.
30. Tavli T., Gocer H. Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure. Jpn Heart J 2002, 43:667-674.
31. Tezcan H., Yavuz D., Toprak A., et al. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003, 4:119-123.
32. Eyileten T., Sonmez A., Saglam M., et al. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010, 15:225-229.
33. Yazici D., Yavuz D.G., Unsalan S., et al. Temporal effects of low-dose ACE inhibition on endothelial function in type 1 diabetic patients. J Endocrinol Invest 2007, 30:726-733.
34. Erzen B., Gradisek P., Poredos P., Sabovic M. Treatment of essential arterial hypertension with enalapril does not result in normalization of endothelial dysfunction of the conduit arteries. Angiology 2006, 57:187-192.
35. Yilmaz M.I., Saglam M., Sonmez A., et al. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007, 25:327-335.
36. Korkmaz H., Karaca I., Koc M., Onalan O., Yilmaz M., Bilen M.N. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. Endothelium 2008, 15:149-155.
37. Wilmink H.W., Banga J.D., Hijmering M., Erkelens W.D., Stroes E.S., Rabelink T.J. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 1999, 34:140-145.
38. Gokce N., Holbrook M., Hunter L.M., et al. Acute effects of vasoactive drug treatment on brachial artery reactivity. J Am Coll Cardiol 2002, 40:761-765.
39. Aznaouridis K.A., Stamatelopoulos K.S., Karatzis E.N., Protogerou A.D., Papamichael C.M., Lekakis J.P. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients. J Hum Hypertens 2007, 21:654-663.
40. Hryniewicz K., Dimayuga C., Hudaihed A., et al. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond) 2005, 108:331-338.
41. Ghiadoni L., Huang Y., Magagna A., Buralli S., Taddei S., Salvetti A. Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens 2001, 19:547-551.
42. Schalkwijk C.G., Smulders R.A., Lambert J., Donker A.J., Stehouwer C.D. ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. Eur J Clin Invest 2000, 30:853-860.
43. Koh K.K., Son J.W., Ahn J.Y., et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 2004, 44:180-185.
44. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005, 45:1088-1093.
45. Anderson T.J., Elstein E., Haber H., Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000, 35:60-66.
46. Watanabe T., Barker T.A., Berk B.C. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005, 45:163-169.
47. Bell L., Madri J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990, 137:7-12.
48. Daemen M.J., Lombardi D.M., Bosman F.T., Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991, 68:450-456.
49. Itoh H., Mukoyama M., Pratt R.E., Gibbons G.H., Dzau V.J. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993, 91:2268-2274.
50. Dostal D.E., Booz G.W., Baker K.M. Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Mol Cell Biochem 1996, 157:15-21.
51. Huckle W.R., Earp H.S. Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res 1994, 5:177-194.
52. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006, 98:887-896.
53. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994, 74:1141-1148.
54. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
55. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980, 32:1-46.
56. Barrow S.E., Dollery C.T., Heavey D.J., Hickling N.E., Ritter J.M., Vial J. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol 1986, 87:243-247.
57. O'Kane K.P., Webb D.J., Collier J.G., Vallance P.J. Local l-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol 1994, 38:311-315.
58. Mombouli J.V., Illiano S., Nagao T., Scott-Burden T., Vanhoutte P.M. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res 1992, 71:137-144.
59. Linz W., Wohlfart P., Scholkens B.A., Malinski T., Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc Res 1999, 43:549-561.
60. Brown N.J., Gainer J.V., Murphey L.J., Vaughan D.E. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000, 102:2190-2196.
61. Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994, 87:567-574.
62. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
63. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
64. Raitakari O.T., Celermajer D.S. Flow-mediated dilatation. Br J Clin Pharmacol 2000, 50:397-404.
65. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
66. Hijmering M.L., Stroes E.S.G., Pasterkamp G., Sierevogel M., Banga J.D., Rabelink T.J. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 2001, 157:369-373.
67. Hornig B., Landmesser U., Kohler C., et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001, 103:799-805.
68. Prasad A., Narayanan S., Husain S., et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000, 102:35-41.